[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coeliac-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coeliac-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,68,91,114,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100638556","interest-of-urinary-measurement-of-immunogenic-gluten-peptides-gip-in-the-follow-up-of-pediatric-celiac-patients-100638556",false,"NCT07578038","Interest of Urinary Measurement of Immunogenic Gluten Peptides (GIP) in the Follow-up of Pediatric Celiac Patients.","GIped","Inclusion Criteria:\n\n* Children aged 2 to 18 years.\n* Confirmed diagnosis of celiac disease according to ESPGHAN criteria.\n* Gluten-free diet followed for ≥ 6 months.\n* Signed informed consent by one of the 2 parents or the legal guardian and oral or written assent from the child.\n* Affiliation to a social security scheme\n\nExclusion Criteria:\n\n* Predictable compliance problem in the study\n* Non-French-speaking patient\n* Seronegative celiac disease at diagnosis\n* Chronic kidney disease\n* Patient protected by law, that is, subject to protective measures (judicial safeguard, guardianship, trusteeship, procedures for opening guardianship and trusteeship measures)","ALL","2 Years","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The main reason for insufficient control of celiac disease is non-adherence to the gluten-free diet (GFD), whether voluntary or involuntary. In children, involuntary exposures are common (canteens, snacks, restaurants). There are no evidence-based recommendations regarding the best way to follow up with patients and assess adherence to the diet. Monitoring of celiac disease is traditionally based on IgA anti-transglutaminase (IgA anti-tTG) serology, but it reflects a delayed immune response and does not detect occasional exposures. Numerous studies conducted outside of France seem to highlight the usefulness of measuring gluten immunogenic peptides (GIP), compared to the current tools used. Measuring GIP in urine, which is non-invasive and can be performed regularly, could allow for earlier and more objective detection of recent gluten exposure, particularly inadvertent exposure, even before symptoms appear. Furthermore, it could serve as a complementary test for patients who continue to show symptoms or positive serology despite a reported well-followed GFD. In such situations, the use of control esophagogastroduodenoscopy (EGD) with jejunal biopsies could be reconsidered in the event of positive urinary GIP. This is the first study conducted in France on the usefulness of urinary measurement of immunogenic gluten peptides in the follow-up of pediatric celiac patients.",[27],"Coeliac Disease",[29],"pediatrics","NOT_YET_RECRUITING","2026-05-04",{"date":33,"type":34},"2026-05-11","ACTUAL",{"date":36,"type":21},"2026-06",{"date":38,"type":21},"2029-06",{"name":40,"class":41},"Fondation Lenval","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100620629","efficacy-of-symprove-probiotics-in-coeliac-disease-100620629","NCT07360106","Efficacy of Symprove Probiotics in Coeliac Disease","A Proof-of-Concept Study to Assess the Efficacy of Symprove Probiotics in Managing Persistent Gastrointestinal Symptoms in Adult Coeliac Disease Patients in Histological Remission","Inclusion Criteria:\n\nAdults aged 18-65 years with biopsy-confirmed coeliac disease (CD)\n\nNormal duodenal biopsy (Marsh 0 or Marsh I) within the last 12 months, confirming histological remission\n\nAdherence to a strict gluten-free diet (GFD) for at least 6 months\n\nPersistent gastrointestinal (GI) symptoms for at least 6 months despite adherence to GFD and histological remission\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nActive gluten ingestion or non-adherence to a gluten-free diet\n\nUse of antibiotics within the past 3 months\n\nUse of probiotics within the past 3 months\n\nKnown comorbidities affecting gastrointestinal function (e.g., Crohn's disease, ulcerative colitis, irritable bowel syndrome with severe diarrhea, or other significant gastrointestinal disorders)\n\nPregnancy or lactation\n\nInability to provide informed consent","65 Years",{"count":52,"type":21},24,[24],"Coeliac Disease (CD) is a lifelong autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) causes damage to the small intestine. It affects around 1 in 100 people. Most individuals feel better and their gut heals after switching to a strict gluten-free diet. However, up to 1 in 5 people with coeliac disease continue to experience unpleasant gut symptoms-such as bloating, pain, and diarrhoea-despite following the diet and having a healed intestine. These ongoing symptoms can be very distressing and impact daily life.\n\nThis study investigates whether a food supplement called Symprove, a probiotic drink containing live good bacteria, can help relieve these ongoing symptoms. Scientists believe that in some people with coeliac disease, the community of bacteria in the gut (called the microbiota) becomes unbalanced, even after going gluten-free. This imbalance (known as dysbiosis) may lead to inflammation, irritation, and symptoms similar to irritable bowel syndrome (IBS).\n\nThe aim of this study is to test whether Symprove can help correct this imbalance and reduce symptoms. Participants will take Symprove daily and their symptoms, quality of life, and gut bacteria (measured from stool samples) will be monitored over time.\n\nThe study hopes to answer three key questions: Can Symprove reduce gut symptoms in people with coeliac disease who are in remission? Does it work by restoring a healthy balance of gut bacteria? Are people with more severe imbalance (dysbiosis) more likely to have symptoms?\n\nIf successful, this research could offer a safe, non-drug option to improve life for coeliac patients who continue to suffer symptoms despite avoiding gluten. It could also help suggest that gut bacteria play a role in ongoing symptoms and are a target for future treatment.",[27,56,57],"Probiotic","Gluten","RECRUITING","2026-03-16",{"date":61,"type":34},"2026-03-17",{"date":63,"type":34},"2026-01-29",{"date":65,"type":21},"2026-12",{"name":67,"class":41},"Sheffield Teaching Hospitals NHS Foundation Trust",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100606207","virtual-dietetic-interventions-in-patients-with-coeliac-100606207","NCT07172555","Virtual Dietetic Interventions in Patients With Coeliac","The Role Of Virtual Dietetic Interventions In Patients With Coeliac Disease","Inclusion Criteria:\n\nPatients aged 18 years and over with serology- or biopsy-proven coeliac disease.\n\nExclusion Criteria:\n\nPatients under the age of 18 years. Patients unable to provide written informed consent. Patients who are unable to understand or speak English. Patients unable to access digital resources. Poly-diagnosis that requires additional nutritional intervention (i.e. Diabetes or Inflammatory Bowel Disease).",{"count":76,"type":21},60,[24],"This clinical study is exploring whether a pre-recorded, on-demand webinar led by specialist dietitians can be as effective as traditional one-on-one appointments in helping people newly diagnosed with coeliac disease learn to follow a gluten-free diet. Coeliac disease is a serious, life-long condition where eating even tiny amounts of gluten, a substance found in wheat, barley, and rye, can cause damaging symptoms and long-term health problems. The only current treatment is sticking to a strict gluten-free diet, which can be difficult without proper support and guidance from dietitians.\n\nThe number of people being diagnosed with coeliac disease in the UK is growing, and this is placing extra pressure on NHS dietetic services, which are already stretched. Many patients currently face long waits or do not get any dietetic support at all. To address this, the research team at Sheffield Teaching Hospitals has developed an on-demand, first-appointment webinar to provide immediate access to trusted dietary information, with the aim of improving patient care and saving NHS resources.\n\nIn this study, adults newly diagnosed with coeliac disease at Sheffield Teaching Hospitals will be asked to join one of two groups: one group will receive their first dietitian appointment through the new on-demand webinar, while the other group will have a traditional face-to-face or phone appointment with a dietitian. Both groups will complete short questionnaires to measure their knowledge about the gluten-free diet, their symptoms, how well they are following the diet, and their quality of life, both before and after receiving their dietary support, and again after six months. Blood tests will also be used to monitor health markers.\n\nThe main goal of the research is to find out if the first-appointment webinar is just as effective as traditional appointments in helping patients understand and follow a gluten-free diet, feel satisfied with the support they receive, and achieve good health outcomes. If the study shows that the webinar approach is as good as traditional care, it could mean quicker, easier, and more consistent access to essential dietary support for people with coeliac disease, both locally and across the UK.\n\nHypothesis:\n\nThe study hypothesis is that a dietitian-led, on-demand, pre-recorded webinar for a first appointment is as effective as traditional one-to-one consultations (face-to-face or by phone) in helping newly diagnosed coeliac patients achieve the same standard health outcomes, dietary knowledge, and satisfaction with care.",[27],[81,82,83],"coeliac disease","diet","webinar",{"date":85,"type":34},"2026-03-18",{"date":87,"type":34},"2025-12-01",{"date":89,"type":21},"2027-06-15",{"name":67,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100603871","validation-of-the-cdat-in-the-polish-paediatric-population-100603871","NCT07142148","Validation of the CDAT in the Polish Paediatric Population","Validation of the Celiac Dietary Adherence Test in the Polish Paediatric Population","CD-PL-CDAT","Inclusion Criteria:\n\n* diagnosis of coeliac disease (CD) according to the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) criteria,\n* age from 2 to 18 years of age,\n* consent from legal guardians (and the child in case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria:\n\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients ≥ 16 years of age).",{"count":100,"type":21},20,"OBSERVATIONAL","The English version of the Celiac Dietary Adherence Test (CDAT) will be translated into Polish using the \"forward-backwards-forward\" translation model, with the author's consent (already obtained by the applicants).\n\nThe Polish translation will be performed by two native bilingual speakers of Polish and English. Both translations will be compared and standardised. The Polish version will then be translated into English by two native bilingual speakers of English who are unfamiliar with the original English version. The translation and original will be compared to clarify discrepancies and ensure conceptual equivalence between the versions. The agreed-upon translation will be culturally adapted, if necessary. The items will be reviewed by five experts, and an I-CVI of at least 0.78 will be considered satisfactory content validity.\n\nIn the next step, 10 coeliac disease (CD) patients aged 10 years and older and 10 caregivers\u002Fparents of CD patients under 10 years of age will be asked to rate the clarity of each statement on a Likert scale \\[1 = unclear to 5 = very clear\\]. Questions with a mean score \\\u003C4.0 will be rephrased and re-evaluated.\n\nInternal consistency analysis using Cronbach's alpha and the mean inter-item correlation (AIC) will be used to assess reliability. Convergent validity will be assessed by comparing scale scores with serological marker levels. Confirmatory factor analysis (CFA) will be conducted, taking into account the SRMR fit index.",[27,104],"Celiac Disease in Children","2025-08-26",{"date":107,"type":34},"2025-09-03",{"date":109,"type":21},"2026-09",{"date":111,"type":21},"2027-08",{"name":113,"class":41},"Medical University of Warsaw",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":42},"100587633","supporting-children-and-young-people-to-live-well-with-coeliac-disease-a-rct-100587633","NCT06930924","Supporting Children and Young People to Live Well With Coeliac Disease: A RCT","Evaluation of a Self-help Psychological Intervention to Support Gluten-free Diet Management, Psychological Wellbeing and Quality-of-life in Children and Young People (Aged 7-11) With Coeliac Disease","Inclusion Criteria:\n\nCaregiver(s) with a CYP between 7-11 years of age who report a diagnosis of coeliac disease Willingness to take part in a self-help psychological intervention Participant must have the ability to provide informed consent\u002Fassent. Caregiver(s) who consent to the study will still be able to take part, even if their CYP does not provide assent to complete outcome measures\n\nExclusion Criteria:\n\nFamilies participating in another intervention-based research will not be eligible Participant identified by clinical team as not appropriate (e.g. undergoing treatment for other complex difficulties) English proficiency unsuitable for participation in self-help psychological intervention and\u002F or online survey.","7 Years","11 Years",{"count":124,"type":21},350,[24],"Managing a strict gluten-free diet is crucial for children and young people with coeliac disease. However, this can have adverse effects on psychological well-being and quality of life. Despite appeals from families, clinicians, and researchers, psychological support is not routinely provided to these families. A feasibility project (NCT06007898) adapted existing self-help psychological resources used for food allergy, gastrointestinal disease, and type one diabetes to cater to families dealing with coeliac disease. This feasibility randomised controlled trial was conducted with 100 families and highlighted the viability and acceptability of this self-help resource. This pilot study was conducted in consultation with caregiver(s), clinicians, and CYP living with coeliac disease. These consultations confirmed a lack of support in this area and the enthusiasm for self-help psychological interventions. We will now run a full randomised controlled trial to evaluate the effectiveness of the intervention for caregiver(s) of CYP with coeliac disease in supporting the appropriate management of the gluten-free diet, alongside psychological wellbeing.\n\nFor this trial, 172 families will complete well-being and quality of life questionnaires, along with assessments of their child's gluten-free dietary management. Families will be divided into groups receiving the psychological resources either immediately or after a five-month delay. Follow-up questionnaires will be administered at one, two, and five months for all families, regardless of intervention access. Feedback on the resources and research participation will be gathered. The expectation is that these self-help psychological resources for parents will enhance gluten-free diet management, quality of life for coeliac children and young people, and well-being for parents.",[27,104],[129,130],"Coeliac disease","celiac disease","2025-04-08",{"date":133,"type":34},"2025-04-16",{"date":135,"type":21},"2025-05-01",{"date":137,"type":21},"2026-03-01",{"name":139,"class":41},"University of Surrey",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":162,"locationsCount":42},"100479983","cardiovascular-risk-factors-in-coeliac-disease-a-series-of-studies-100479983","NCT05530070","Cardiovascular Risk Factors in Coeliac Disease: a Series of Studies","ARCTIC","Inclusion Criteria (applies to all subjects):\n\n* Age should be over 18 years.\n* Blood collection must be indicated with medical conditions.\n* Signed informed consent.\n\nInclusion Criteria (applies to specific cohorts of patients):\n\n* The diagnosis of CD should be set up according to the current guidelines (based on serology and histology in adults or as per the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guideline in children).\n* The newly diagnosed CD patients should be on a gluten-containing diet.\n* Patients following a GFD for at least 1 year should exhibit good dietary adherence.\n* In the randomized controlled trial (RCT), strict dietary adherence will be established based on CD-specific serology (normal level of antibodies), urine gluten immunogenic peptides (negative urine test), and dietary interview (convincing knowledge on the GFD and positive attitude towards strict adherence). Adherence to the mediterranean diet should be suboptimal (≤ 8 Medietrranean Diet Score). RCT-patients must have internet access and must be capable to attend the online sessions for 1 year.\n* Control subjects should be free from CD according to the recent guidelines and should be on a gluten-containing diet.\n\nExclusion Criteria:\n\n* Chronic conditions:\n\n  * Estimated glomerular filtration rate calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is \\\u003C60mL\u002Fmin\u002F1.73m2 (CKD3 or more severe kidney failure).\n  * Liver cirrhosis in Child-Pugh class B-C.\n  * Heart failure (New York Heart Association (NYHA) III-IV).\n  * Active malignant diseases.\n* Any acute diseases or acute deterioration of underlying chronic conditions.\n* Diseases that may be associated with clinically relevant malabsorption.\n* Refractory CD.\n* Pregnancy, lactation.\n* Patients unable to understand the essentials of the informed consent.\n* Lack of consent or withdrawal of consent.",{"count":148,"type":21},190,[24],"This investigation examines the most important cardiovascular risk factors (e.g., metabolic parameters, body composition) and their changes in coeliac disease. The series of studies allow to assess body composition and cardiovascular risk-related metabolic parameters of newly diagnosed and treated coeliac patients in their complexity and to test if they change during therapy. The interventional part of the investigation aims to answer the question if a dietary intervention mitigates the unfavorable effects of unbalanced diet.",[27],[81,153,154,155],"cardiovascular risk","body composition","dietary intervention","2025-01-18",{"date":158,"type":34},"2025-01-22",{"date":160,"type":34},"2022-09-01",{"date":65,"type":21},{"name":163,"class":41},"University of Pecs"]